What is PregLem?
Founded in 2006 by Ernest Loumaye and Eric Rolin, PregLem is dedicated to the development and commercialization of novel drugs within women's reproductive health. The company's name itself reflects its mission to address unmet medical needs in gynecology and infertility, coupled with its proximity to Lake Geneva. PregLem leverages the expertise of its Scientific Advisory Board, composed of leading European academic specialists in reproductive medicine, and its internal team's proficiency in clinical product development, regulatory affairs, and sales and marketing within the women's health sector. The company's journey has been marked by strategic financial backing, enabling its growth and development in this specialized therapeutic area.
How much funding has PregLem raised?
PregLem has raised a total of $59.9M across 2 funding rounds:
Series A
$26.9M
Series B
$33M
Series A (2007): $26.9M with participation from Sofinnova Partners and MVM Partners
Series B (2007): $33M led by MVM Life Science Partner and Sofinnova Ventures
Key Investors in PregLem
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. They are known for their hands-on approach, acting as company builders across the entire value chain of life sciences investments.
MVM Partners
MVM Partners LLP invests in innovative healthcare companies, actively supporting businesses that enhance healthcare delivery through quality and cost-effective solutions. Their focus spans medical technology, pharmaceuticals, and digital health.
Sofinnova Ventures
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. They actively partner with ambitious entrepreneurs to develop transformative innovations.
What's next for PregLem?
With a history of substantial enterprise-level funding, PregLem is positioned for continued advancement in its pipeline of women's reproductive health solutions. The recent major strategic investment signals confidence from its backers in the company's potential to capture significant market share and address critical unmet needs. Future endeavors will likely focus on advancing clinical trials, navigating regulatory pathways, and preparing for the commercial launch of its innovative therapies, further solidifying its role as a key player in the biopharmaceutical landscape for women's health.
See full PregLem company page
